drugset / Trial / NCT04401137
The Evaluation of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX in Healthy Korean Male Subjects
RandomizedParallel-groupDouble-blindPrevention
Summary
To evaluate pharmacokinetic/pharmacodynamic characteristics and safety of QDX after single oral administration in healthy Korean male subjects
Timeline
- Start
- 2020-07-01
- Primary completion
- 2020-10-06
- Completion
- 2020-10-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Topiramate | Small molecule | 25 mg | Oral |
| Subject | Topiramate | Small molecule | 50 mg | Oral |
| Subject | Topiramate | Small molecule | 100 mg | Oral |
| Subject | Topiramate | Small molecule | 200 mg | Oral |